BDX: A Long-Term Business Owner's Investment Analysis

Hunting ten-year five-baggers among great growth stocks — pressing the upside question: "Can it get much bigger?"

• QHow high is its market ceiling? Is it growing a piece of an existing pie, or creating an entirely new market?4/10

  A

  Conclusion: BDX is growing a piece of a huge, stable, mildly growing existing pie, not creating a brand-new market — measured against Baillie Gifford LTGG's "five times in ten years" yardstick, this is its most fundamental hard constraint. It sells needles, tubing, infusion sets, blood-collection devices, pharmacy automation, ICU monitoring, interventional devices, and drug-delivery components that hospital systems use every day — categories that already exist with confirmed demand, but whose ceiling rises at the pace of population-level slow variables such as "aging + chronic disease + inpatient/outpatient activity volume," not the pace of a category exploding from nothing.

  The "height" of the ceiling shows up in absolute scale rather than in slope. After the Waters spin-off, New BD remains one of the largest pure-play medical technology companies globally; on the company's stated FY2025 comparable basis, revenue was about $18.544 billion (per this report), and FY2026 Q2 single-quarter revenue already reached $4.714 billion, up 5.2% year over year, or only +2.6% on a currency-neutral basis. That growth rate is exactly the point: the addressable pool is large, but it can only "mildly drift up" each year with the underlying activity level of the healthcare system, and the company's full-year guidance is also just "low single digit" revenue growth.

  Looking more closely at the four segments, none of them is a "new continent" story: Medical Essentials (basic injection/infusion/blood-collection consumables) is an already highly penetrated, stock-replacement market; Connected Care (pharmacy automation, monitoring, infusion systems) is deepening its embedding within existing hospital IT/pharmacy workflows; Interventional (interventional/surgical/urology devices) is fighting mature peers for share; BioPharma Systems (biopharma drug-delivery systems) has relatively the most "growing the pie" flavor — it has caught the genuine incremental wave of GLP-1, with biologics now accounting for about 55% of that segment's revenue, and the company has also signed two next-generation GLP-1 major-customer programs and more than 80 GLP-1 biosimilar agreements. But BioPharma Systems' Q2 revenue was only $590 million, the smallest of the four segments, too small to move the overall ceiling's slope.

  To be honest, the report itself rates industry attractiveness 4/5 and states plainly that "the industry is not high-growth, but demand resilience is strong." For Baillie Gifford's preference for "heavy upside imagination, five times in ten years," BDX's market falls into the category of "certain but not sexy": you almost never have to worry about demand disappearing, but you also can't expect a mildly growing, stock-replacement market to hand a single company a five-fold revenue leap over ten years. Its upside relies more on share capture (such as Alaris's +150 basis points of competitive share year-to-date) and profit-quality repair, rather than the market ceiling itself being pushed higher.

  Jun 10, 2026
• QCan its revenue at least double over the next five years? Is growth mainly driven by volume, price, or new business?2/10

  A

  Conclusion: Almost impossible. Doubling revenue in five years requires a compound growth rate of about 15% per year; New BD's current real-world rate is the company's own guided "low single digit", and Q2's currency-neutral rate was only +2.6%. Starting from this base, five years of natural growth can roughly only grow revenue by about 15%-25%, an order of magnitude short of doubling. This is precisely the item where BDX falls shortest under the Baillie Gifford LTGG framework — it is not a growth engine that can multiply revenue several times over in ten years, but a deep-draft, steady-speed medical consumables supertanker.

  Breaking down the sources of growth, none of the three engines is enough to support a doubling:

  Volume: the main driver, but only mild. The driving forces are population-level slow variables like aging and chronic-disease management and inpatient/outpatient activity volume, layered with share capture. The most concrete volume-growth highlight is Alaris: both this report and the company confirm +150 basis points of competitive share year-to-date, +50 basis points in Q2 alone, and zero infusion account attrition that quarter, driving low-double-digit consumables growth. But share capture is "cutting a bigger slice from an existing pie," and its ceiling is limited.

  Price: essentially not something to count on, and even a headwind. The report explicitly notes that BDX's pricing power is "uncertain" — hospitals wield reverse bargaining power through GPOs/IDNs, and China's volume-based procurement (VBP) and medical cost controls keep pressing on price. As a matter of fact, in Q2 tariffs alone knocked 160 basis points off adjusted gross margin, and overall adjusted gross margin fell 90 basis points year over year, with the company only able to partly offset this through productivity gains. This shows it cannot even pass costs through to customers painlessly, let alone drive a doubling through price increases.

  New business: the only thing with any "incremental" flavor is GLP-1 within BioPharma Systems. The company has signed two next-generation GLP-1 major-customer programs plus more than 80 GLP-1 biosimilar agreements, with biologics now about 55% of that segment's revenue. This is a genuine wave worth liking. But the segment's Q2 revenue was only $590 million, the smallest of the four segments — even growing rapidly, it can only be a marginal contributor to a roughly $18.5 billion total pool (per this report's FY2025 New BD basis), not enough to support an overall doubling.

  Honest conclusion: doubling BDX's revenue in five years is unrealistic; growth is mainly "volume," "price" is a headwind, and "new business" is a marginal bright spot. The report's positioning of it as a "stable-demand, not-weak-moat, but not high-growth" defensive platform is accurate. For investors seeking five times in ten years, this is the dimension that should be marked down the most.

  Jun 10, 2026
• QFive years from now, what will take over as the next growth engine? Does this "second curve" exist today?4/10

  A

  Conclusion: BDX has no disruptive second curve capable of "taking over and remaking the company" five years from now; what it has are a few already-existing "curve 1.5s" that can only marginally lift the growth rate. This is quite far from what Baillie Gifford LTGG expects — "an entirely new main curve emerging in years 3-10" — BDX looks more like it is extending and thickening its main curve rather than incubating the next independent growth pole.

  There are three "quasi-second-curves" visible and genuinely present today:

  First, GLP-1 drug delivery within BioPharma Systems. This is the closest thing to "genuine incremental growth": the company has already signed two next-generation GLP-1 major-customer programs plus more than 80 GLP-1 biosimilar agreements, with biologics about 55% of that segment's revenue. The wave of weight-loss drugs and chronic-disease injectables is a genuine long runway. But qualitatively, it is "the core business (prefillable syringes, delivery components) riding volume from a new drug class" — fundamentally still BDX's old trade sold into new demand — and that segment's Q2 revenue was only $590 million, too small in scale to take over as the company's primary engine within five years.

  Second, Connected Care's "device-software-data" loop. The report notes that Connected Care's device-software-data loop "has some platform stickiness"; if Alaris, Pyxis, monitoring, and pharmacy automation can monetize software/data, this could in theory open a higher-quality curve. But the report also honestly marks its data advantage as only "moderate" and network effects "weak to moderate," not yet reaching "an extremely strong data network effect" — meaning this curve is potential today, not realized.

  Third, share-recovery-type growth (such as Alaris's +150bps of share after returning to the market). Strictly speaking this is not a "new curve" but a "recovery bounce of an old curve after being suppressed by regulatory remediation," and its ceiling is simply its original market share.

  Honestly, the report's own judgment on growth engines is already conservative — it sets full-year guidance at "low single digit" revenue growth and does not describe any single business line as "an about-to-take-over breakout engine." Treating "a more focused business post-spin-off" as the biggest narrative in fact reinforces that BDX's story is "solidifying the existing platform," not "incubating the next ten-x business." Under the Baillie Gifford framework, this item can only get a neutral-to-weak score: the second curve has a rudimentary shape today, but it is neither large enough nor new enough — it looks more like a natural extension of the main curve.

  Jun 10, 2026
• QWhat is its core competitive advantage? Will this moat widen or narrow over the next three to five years?5/10

  A

  Conclusion: BDX's core moat is a stack of "installed base + high switching costs + consumables repurchase + regulatory/channel access barriers," real in strength but not top-tier; over the next three to five years it will most likely "stay stable, widening mildly" rather than expanding sharply or shrinking quickly. The report scores the moat 4/5 and marks its state as "stable-to-shrinking, awaiting re-validation" — I agree with the caution behind that judgment, but based on the latest operating data, at least on the core infusion battlefield, the moat is in fact re-widening.

  Of the moat's sources (as broken down in the report, which I have checked item by item), the two most solid are switching costs and consumables repurchase: Alaris, Pyxis, monitoring platforms, pharmacy automation, and hospital IT/EMR/consumables are deeply intertwined, not "buy today, replace tomorrow." Per the report, the company has a consumables-type revenue mix of over 90%, and some medication management contracts still carry about $2 billion of unfulfilled minimum consumables purchase commitments (per this report), making revenue highly predictable. Scale advantage is also strong — global manufacturing, quality systems, and regulatory registration barriers are extremely high. Relatively weaker are network effects (weak to moderate), brand (mindshare among professionals, not a consumer brand), data advantage (moderate), and, as the report itself notes, no single patent independently defines its entire competitive advantage, and patents eventually expire.

  The evidence of "widening" over the next three to five years: after regulatory remediation, Alaris has staged a strong recovery, with +150 basis points of competitive share year-to-date, +50 basis points in Q2, zero infusion account attrition, and the company describing it as facing "the largest Alaris competitive funnel ever". Rising share plus an expanding installed base will self-reinforce consumables repurchase, which is direct evidence of a widening moat. Post-Waters-spin-off, the business is more focused and management attention more concentrated, which also helps maintain the moat.

  The pressure toward "narrowing" is equally real and must be counted honestly: hospital-side GPO/IDN reverse bargaining power, and China's volume-based procurement plus medical cost controls, continue to erode pricing power (the report judges pricing power "uncertain"); quality/regulatory tail risk (Alaris remediation, FDA 510(k) matters and Warning Letters, product remediation) is a recurring legacy issue that would directly weaken customer trust if it escalates again; tightening sterilization (ethylene oxide) regulation could raise costs and disrupt supply. None of these would make the moat "suddenly disappear," but they continuously add "friction" to it.

  Qualitative overall assessment: the moat's strength is real (consistent with the report's 4/5), and directionally I am one notch more optimistic than the report's "leaning-toward-shrinking" phrasing — on the core infusion battlefield we can already see hard data of "re-widening" — but the whole picture is still constrained by hospital bargaining and regulatory tail risk, and the most likely state is "widening mildly over 3-5 years, but not breaking out of the medical device industry's ceiling." It is a moat "deep enough not to be easily filled in," but not the kind that "runs ever wider and automatically devours the market" like a compounding moat.

  Jun 10, 2026
• QIf its core business were disrupted, does it have the DNA to reinvent itself? How does it treat mistakes and bad news?4/10

  A

  Conclusion: What BDX demonstrates is "steady error-correction and portfolio-reset capability," not, in the Baillie Gifford sense, "the DNA to start over when the core business is disrupted." It is good at fixing quality issues, restructuring its portfolio, and recovering lost ground within its existing medical device footprint; but it is not the kind of company that "can leap to an entirely new track and be reborn after its main business is overturned by a technological revolution." Given it operates in a market of confirmed, slow-changing medical necessity, the probability of "being disrupted wholesale" is not high to begin with — the report's judgment is correct: business-model disruption "is unlikely to come from demand disappearing, more likely from a combination of quality incidents + regulatory constraints + customer workflow substitution + lower-price competition."

  Positive: the evidence of error-correction and reset is concrete. First, it does not shy away from mistakes — the report candidly acknowledges the company has had Alaris-related remediation, FDA Warning Letters, product remediation, and historical SEC investigations and disclosure issues, all of which are publicly acknowledged and continuously being dealt with, not covered up. More important is the outcome: after its darkest hour of regulatory remediation, Alaris has staged a strong comeback, with +150 basis points of competitive share year-to-date, zero infusion account attrition in Q2, and facing the largest competitive funnel ever — hard evidence of "climbing back from a major regulatory blow and winning back customers," showing its error-correction mechanism can translate into commercial results. Second, portfolio resets have been decisive — in February 2026 the company completed the combination and spin-off of Biosciences & Diagnostic Solutions with Waters, valued at $18.8 billion, in exchange for $4 billion in cash, proactively divesting a less-focused business — showing a willingness to "admit the old structure was suboptimal and act to restructure." Third, the BD Excellence operating system has delivered results (rated moderate by the report).

  Shortfall: it lacks the DNA to "switch tracks and be reborn." The report rates corporate culture only "moderate" and states plainly that "quality and compliance shortcomings show it is not perfect"; management and capital allocation get only 3/5. Historically BDX has relied too heavily on M&A and amortization to bridge growth, which has kept ROIC in the 4%-5% range for a long time, with a wide gap between GAAP and adjusted figures — reflecting that its "reinvention" tends to be "buy it and then integrate it," rather than "incubate an entirely new capability internally." This kind of path would tend to turn more slowly when hit by a genuine wave of technological substitution.

  Qualitatively, its attitude toward bad news is "honest disclosure, steady handling, but not especially clean or crisp": it does not hide the landmines — it puts quality/regulatory baggage on the table and follows up quarter by quarter — but the large adjustment items and recurring compliance shortcomings also show the root causes are not being fully resolved. On balance, this item is neutral: BDX has a reliable "self-repair within its own trade" DNA, but not a "self-reinvent-as-another-company-after-disruption" DNA — fortunately, the nature of its business means the latter test is unlikely to arrive.

  Jun 10, 2026
• QDoes management (especially the founder) have a long-term view, with interests deeply tied to the company? Are they willing to sacrifice near-term profit for the sake of five to ten years out?4/10

  A

  Conclusion: Management is a "institutionally long-term-minded, compliant incentive design, increasingly rational portfolio allocation" team of professional managers, but not the kind of "founder holding a huge stake, deeply tied to the company's fate" team that Baillie Gifford favors most. BDX is a mature company with more than 100 years of history, long past the era of founder leadership; as of December 1, 2025, CEO Tom Polen held about 527,589 shares (per this report), which at the current price of about $152 works out to roughly $80 million — not a small sum in absolute terms, but the report accurately points out it does "not reach the founder-level 'all-in, sink-or-swim' scale." This item is a natural structural shortfall for BDX against Baillie Gifford's ideal model.

  Interest alignment: compliant on paper, moderate in strength. The report confirms: executives have explicit stock-ownership requirements (CEO 6x annual salary, other executives 3x annual salary), there are clawback provisions, prohibitions on pledging and hedging, and no change-in-control tax gross-up; annual incentives are tied to revenue, adjusted EPS, operating margin, and free cash flow conversion, while long-term incentives use revenue growth and ROIC, modified by relative TSR. This design is competent, even above-average, at "preventing short-term arbitrage and constraining executive behavior," and putting ROIC into the long-term incentive is especially well targeted (since ROIC is precisely BDX's pain point). But "holding shares by rule" and "founder-style voluntary heavy ownership" are two different things — the former is naturally a notch weaker in the strength of its long-term conviction.

  Willing to sacrifice near-term profit for five to ten years out: the direction is right, but hardly aggressive. The strongest evidence is the shift in capital allocation: taking the $4 billion in cash from the Waters transaction and splitting it between accelerated buybacks (roughly $2 billion) and about $2.1 billion of debt repayment, rather than "keep doing large-scale M&A" — more rational than the past, reflecting a trade-off in favor of long-term balance-sheet health. Combined with 54 consecutive years of dividend increases (annual dividend of $4.20/share) and a maintained investment-grade credit rating, this shows some long-term discipline. But note that the combination of buybacks + debt paydown + steady dividends looks more like "steady stewardship" than "loading up on near-term pain for a ten-year vision" — what Baillie Gifford wants to see more is the latter kind of nerve, and BDX is restrained on this front.

  The discount to trust: The report rates management and capital allocation 3/5 and marks both "is management trustworthy" and "is capital allocation rational" as "uncertain." The reason is a long history of reliance on M&A and large adjusted-metric narratives, a wide gap between GAAP and adjusted figures, and ROIC that will not lift. That is not the same as dishonesty, but it does weaken the sense of "clean profit quality."

  Overall qualitative view: this is a "compliant, rational, recently improving in capital allocation" mature management team, rated neutral-to-slightly-positive; but it lacks founder-style deep interest alignment and the strong conviction to "sacrifice the present for the distant future," which is a structural deduction under the Baillie Gifford yardstick. To raise conviction here would require seeing ROIC genuinely lift and the GAAP/adjusted gap genuinely narrow over the next 2-3 years.

  Jun 10, 2026
• QIf it disappeared tomorrow, how much would customers miss it? Is its growth model sustainable, without relying on harming society or gaming regulation?6/10

  A

  Conclusion: If BDX disappeared tomorrow, hospitals and pharma companies would miss it a great deal — its products are clinically essential, deeply embedded "infrastructure-grade" fixtures in workflows; and its growth model is highly healthy, built on positive externalities like patient safety, infection control, and medication accuracy, where "more is better," with almost no element of "growth by harming society or gaming regulation." This is one of the few items under the Baillie Gifford framework where BDX stands firmly on both ends.

  Indispensability: strong. BDX sells basic injection/infusion/blood-collection consumables, pharmacy automation, ICU monitoring, interventional devices, and drug-delivery components — things the healthcare system uses every day and that clinically cannot function without. The report notes its consumables-type revenue mix of over 90% and about $2 billion of unfulfilled minimum consumables purchase commitments (per this report), showing customers are not "occasional buyers" but have BDX embedded in the bloodstream of daily operations. The most direct quantified evidence of "how much it is missed" comes from Alaris: when it once withdrew from the market due to regulatory remediation, hospitals endured real replacement pain; now that it has staged a strong comeback, with +150 basis points of competitive share year-to-date, zero infusion account attrition in Q2, and facing the largest competitive funnel ever — customers have voted by "buying it back." High switching costs and deep installed-base ties mean "disappearing" would be a high-cost event for customers.

  Social/regulatory sustainability: healthy — this is the foundation of the business, not a burden. BDX's growth engines are aging, chronic-disease management, injection/infusion safety, infection control, and blood/sample management — all directions that regulators and society want to see "done more and better," not gray areas policed by regulators or exploited via information asymmetry or externalities. The more successful it is, the safer patients are and the more accurate medication delivery becomes — aligned with public-health goals. The recently boarded GLP-1 delivery wave (two next-generation GLP-1 major customers plus more than 80 biosimilar agreements) likewise serves genuine clinical need.

  The "other side" that must be honestly noted — regulation cuts both ways for it. The risk from BDX's indispensability is not "it harms society," but that "high regulatory standards for essential medical products can bite back into profit": the report explicitly lists FDA 510(k)/Warning Letter matters, Alaris remediation, product remediation, tightening sterilization (ethylene oxide) regulation, and China's volume-based procurement and medical cost controls. In other words, its growth does not itself harm society, but as an indispensable medical supplier it must continually bear the cost of strict regulation and the tail risk of quality compliance. This is the standard price of "a good business under heavy regulation," not a stain of "harming society for growth."

  Overall qualitative view: this item scores high — strong indispensability, positive social value, sustainable growth, harming no one. The only thing to factor in is the inherent compliance cost and quality tail risk of a "highly regulated necessity," but that is an obligation, not an original sin.

  Jun 10, 2026
• QWhat are this business's unit economics (gross margin, incremental returns) like? Do they improve or worsen as scale grows? Where does the money earned get spent?5/10

  A

  Conclusion: BDX's unit economics are a combination of "above-average gross margin + mediocre incremental return on capital" — the consumables business itself is profitable with a decent gross margin, but growing scale has not lifted the return on capital; instead it has been dragged down for years by M&A integration, intangible amortization, and quality remediation. Money earned has recently shifted toward "buybacks + debt paydown + dividends," a more rational direction than in the past. This is the most critical "quality shortfall" for BDX on the Baillie Gifford yardstick: a good business does not equal a good return on capital.

  Gross margin and operating margin: decent, but the GAAP-to-adjusted gap is too wide. Per FY2025 disclosures (as reported here), GAAP gross margin was about 45.4%, GAAP operating margin about 11.8%, while adjusted operating margin was about 25.0%. The latest quarter confirms this picture: Q2 adjusted operating margin was 24.2%, and adjusted gross margin fell 90 basis points year over year (tariffs alone cost 160 basis points, partly offset by 70 basis points of productivity gains). The report puts it bluntly: the problem "is not that gross margin is too low, but that the gap between GAAP and adjusted is too wide" — meaning a good chunk of the "beautiful unit economics" on the reported statements is propped up by adjustment items.

  Incremental returns: this is the real weak spot. Third-party public data show BDX's ROIC at about 4.5%, long below its weighted average cost of capital (WACC), sitting in "value-eroding" territory, and the report likewise gives FY2021-FY2025 ROIC of roughly 4.2%-4.6% and ROE of 6.0%-6.8%. The comparison against peers is more glaring: Medtronic's ROIC is about 7.98%, Boston Scientific's about 9.85%, Thermo Fisher's about 8.03% — BDX is at the bottom of this group. This directly answers "does it improve or worsen with scale": BDX has grown scale substantially, but incremental return on capital has not improved along with it, because much of its growth has come from "buying it via M&A," and the output efficiency of each new dollar of invested capital is on the low side.

  The good side: cash profit is real, and assets are not heavy. The report notes FY2023-FY2025 free cash flow all exceeded GAAP net income, showing substantial amortization/non-cash charges are depressing accounting profit and the cash is not paper wealth; capex is only about 3.5%-6% of revenue, not a business that has to keep pouring money into heavy-asset factories to operate. In other words, the "cash foundation" of the unit economics is healthy; the problem is that "the price paid in M&A for growth" is dragging down overall capital efficiency.

  Where the money earned gets spent: recently, a clear shift toward shareholder returns and deleveraging. The $4 billion in cash from the Waters transaction went $2 billion to accelerated buybacks and about $2.1 billion to debt repayment, on top of 54 consecutive years of dividend increases ($4.20/share). This is far more rational than the old path of "continuous large M&A." But the report also warns that if it returns to a large-M&A cadence in the future, shareholder returns could continue to be diluted, and ROIC could continue to fail to lift.

  Overall qualitative view: unit economics score neutral-to-weak — decent gross margin and real cash are pluses, but ROIC persistently below the cost of capital and scale not delivering incremental returns are structural minuses. The direction of capital deployment has recently improved, but whether ROIC can truly be lifted is the deciding factor over the next 2-3 years for whether "a good business" turns into "good shareholder returns."

  Jun 10, 2026
• QWhat conditions would all need to hold simultaneously for it to rise five-fold in ten years? Are those conditions realistic? What expectations does today's share price imply?3/10

  A

  Conclusion: For BDX to rise five-fold in ten years (about 17.5%/year), a chain of low-probability conditions would need to hold simultaneously — and this is exactly the toughest hurdle for it under the LTGG framework. Realistically, a five-fold rise in ten years is nearly impossible; even the report's own bull-case estimate of expected annualized return is only about 11%-13%. At today's price of about $152, what is implied is not "high-growth expectations," but the real-world pricing of "low growth + mediocre capital efficiency + a regulatory discount."

  Conditions that would all need to hold for a five-fold rise in ten years (checked one by one against reality, nearly all falling short):

  1. Revenue must accelerate significantly. A five-fold rise requires at least a revenue-doubling-scale contribution, corresponding to a sustained growth rate of 7%+. Reality: the company guides "low single digit," and Q2 currency-neutral growth was only +2.6%. A huge gap.

  2. ROIC must rise from 4%-5% into the double digits. This is the precondition for a profit-quality re-rating. Reality: ROIC is about 4.5%, long below WACC, far below MDT's about 8% and BSX's about 9.85%, and lifting it would take years of execution.

  3. The GAAP/adjusted gap must narrow and profit quality must "clean up." Reality: the report notes the gap between the two is "too wide," a long-standing chronic issue.

  4. The valuation multiple must recover substantially. Reality: current EV/EBITDA is about 12.1x, and it would need to recover to peers' 15-19x.

  5. No major new quality/regulatory event within ten years, and deleveraging must continue (currently Net Debt/EBITDA is about 3.33x). Any Alaris/FDA/sterilization escalation would interrupt the compounding.

  Having five conditions all hold simultaneously over ten years, for a mature, low-growth, regulation-entangled medical device company, is a compounding of low-probability events. This report's implicit stance on "five times in ten years" is likewise restrained — per this report, the ideal buy range given is only $120-135, the base-case intrinsic value range $154-178, and even the bull scenario only $217-249, with corresponding expected annualized returns of 7%-9% base case and 11%-13% bull case — none of which points to a five-fold return.

  What expectations does today's share price imply: low expectations, not high ones. At today's price of about $152, market cap about $41.9 billion (note: slightly above the $147.63/$40.68 billion at the time this report was written), corresponding to EV/EBITDA of about 12.1x, below peers. What the market's pricing says is "BDX is a mildly growing, ROIC-challenged, steady platform carrying a regulatory/quality discount" — it has not paid any premium for "five times in ten years"; if anything, it has discounted against that. The double-edged implication is: precisely because expectations are low, BDX's upside is more likely to come from "valuation recovery + mid-single-digit growth + improving cash flow," a 7%-13%-scale return, rather than a five-fold growth re-rating.

  Overall qualitative view: this item scores low — the conditions are demanding and reality doesn't support them. But to be clear, that doesn't make BDX a bad investment; rather, its return shape was never Baillie Gifford-style "exponential growth" to begin with, but value-style "a reasonable price + mild compounding + discount recovery." The share price implies the latter, not the former.

  Jun 10, 2026
• QWhy hasn't the market recognized all this yet? Is it a failure to understand, to respect, or to see far enough? What would become the "narrative inflection point"?3/10

  A

  Conclusion: On BDX, the question of "why hasn't the market recognized this yet" needs to be flipped around — the market has actually seen it quite clearly; BDX's low valuation is not a mispricing but a fair pricing of "low ROIC + regulatory/quality discount + mediocre growth." This is exactly where the report is most restrained and most honest: it does not package BDX as "a wrongly punished hidden champion," but acknowledges that part of the discount is "structural." Baillie Gifford's core question is "why hasn't the market recognized its greatness" — and for BDX, the answer is mostly that it simply isn't that "great," and the market hasn't gotten it wrong.

  Breaking it down via the "fail to understand / fail to respect / fail to see far" framework:

  • Fail to understand? Only a small part of it. BDX does have genuinely "hard to understand" aspects: the report notes it is heavily involved in M&A, intangible amortization, quality remediation, spin-off restructuring, and one-time charges, resulting in too wide a gap between GAAP and adjusted profit (Q2 adjusted operating margin was 24.2%, but GAAP operating margin was far lower), requiring real effort to separate reported profit from distributable cash flow. New BD's short standalone full-year cash-flow history post-spin-off also adds to the difficulty of seeing clearly. This portion of "not understanding" may be depressing the valuation somewhat — but it is genuine complexity, not market foolishness.

  • Fail to respect? This is the main reason, and it is reasonable. The market "does not respect" BDX because it genuinely falls short on several hard metrics: ROIC of about 4.5%, long below WACC, in value-eroding territory, far inferior to MDT's about 8% and BSX's about 9.85%; growth of only low single digit; Net Debt/EBITDA of about 3.33x, on the high side; and it still carries FDA/Alaris/sterilization regulatory tail risk. Giving it EV/EBITDA of about 12.1x, below peers' 15-19x, is a fair reflection of "average quality + complex governance + a regulatory discount," not a mistake. The report's own strongest bear case gets it right: "the market giving it a low multiple is not a mistake, but a fair reflection of average capital efficiency + complex governance + a quality discount."

  • Fail to see far enough? This is the only decent potential source of opportunity. If there is any mispricing, it can only be that "the market is linearly extrapolating the current low ROIC and regulatory baggage, underestimating the improvement that would come from post-spin-off focus + the Alaris recovery + GLP-1 ramp + deleveraging." The recent positive signals are real: Alaris's +150bps of share year-to-date and zero account attrition, the $4 billion received from the Waters spin-off, split between $2 billion of buybacks and $2.1 billion of debt paydown, and FY2026 adjusted EPS guidance raised to $12.52-12.72. If these continue to be delivered, the market "seeing a bit further" could reward a valuation recovery.

  What would become the narrative inflection point: The inflection point will not come from "the market suddenly discovering BDX is great," but from "BDX proving, quarter after quarter with hard data, that it is no longer mediocre." The concrete inflection signals are the same set of aligned improvements the report lists — (1) New BD's standalone free cash flow stably holding above $2.6 billion, (2) ROIC substantively lifting from 4%-5%, (3) the GAAP/adjusted gap narrowing meaningfully, (4) Net Debt/EBITDA continuing to fall, and (5) Alaris/GLP-1-driven organic growth accelerating with no new major regulatory event. Only if three or four of these are delivered consecutively will the "low-ROIC, low-trust discount" narrative be rewritten and the multiple re-rated. Conversely, if ROIC still cannot lift and the company returns to the old path of large M&A, today's "cheapness" will be confirmed as the prelude to a value trap — the very symmetric risk the report repeatedly emphasizes.

  Overall qualitative view: this item scores neutral-to-weak — the market has broadly gotten it right; BDX is not a wrongly punished great company but a fairly priced "reasonable-price company." The real window of opportunity lies only in "whether the market is being too short-sighted and underestimating the improvement," and that requires management to deliver over 2-3 years of execution; the narrative inflection point is "proof-driven," not "discovery-driven."

  Jun 10, 2026